Skip to Main Content
our new site.
NLM Technical Bulletin
Full Text View
A Crossover Study to Evaluate the Safety, Tolerability and Efficacy of XPF-002 in Subjects With Postherpetic Neuralgia (PHN) (XEN402)
This study has been completed.
Study NCT01195636 Information provided by Xenon Pharmaceuticals Inc.
First Received on August 31, 2010. Last Updated on September 20, 2013
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Additional conditions recognized in this trial
More general conditions related to this trial
Nervous System Diseases
Peripheral Nervous System Diseases
Signs and Symptoms
Interventions listed in this trial
Sponsors listed in this trial
Xenon Pharmaceuticals Inc.
Back to top of Main Content
Contact Help Desk
Lister Hill National Center for Biomedical Communications
U.S. National Library of Medicine
U.S. National Institutes of Health
U.S. Department of Health & Human Services
Freedom of Information Act
Links to all studies - primarily for crawlers